etidronic acid   Click here for help

GtoPdb Ligand ID: 7184

Synonyms: Didronel® | etidronate disodium
Approved drug PDB Ligand
etidronic acid is an approved drug
Compound class: Synthetic organic
Comment: Etidronic acid is a bisphosphonate drug.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: etidronic acid

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 5
Rotatable bonds 2
Topological polar surface area 154.91
Molecular weight 205.97
XLogP -3.81
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(P(=O)(O)O)(P(=O)(O)O)O
Isomeric SMILES CC(P(=O)(O)O)(P(=O)(O)O)O
InChI InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
InChI Key DBVJJBKOTRCVKF-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Bisphosphonates are used to treat and prevent disorders such as hypercalcaemia, osteoporosis and Paget’s disease, and bone disorders and tissue calcification in cancer patients. There is no information regarding approval for clinical use of this drug on the US FDA website. Other national approval agencies may have granted marketing authorisation.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
By shifting the equilibrium of bone resorption/formation towards the formation side by various potential mechanisms, drug treatment makes bone stronger. This drug may also cause apoptosis of osteclasts (bone resorbing cells) by antagonising ATP in energy metabolism which ties with ChEMBL listing the target of this drug as ATP. See the DrugBank link for further details.
As the precise mechanism of action of this drug is not fully resolved, we have not tagged a primary drug-target interaction.